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Abstract
Background: In cancer patients, MUC1 glycoprotein may carry Lewis y which could be involved in immune response. Purposes:
1- to evaluate the presence of Lewis y and MUC1 in circulating immune complexes (Lewis y/CIC and MUC1/CIC, respectively)
and their correlation; 2- to analyze the possible presence of Lewis y in carbohydrate chains of tumoral MUC1 glycoprotein and
3- to correlate serum and tissue parameters considered.
Methods: Pretreatment serum and tissue breast samples from 76 adenocarcinoma, 34 benign and 36 normal specimens were
analyzed. Anti-MUC1 and anti-Lewis y MAbs were employed. To detect Lewis y/CIC and MUC1/CIC, ELISA tests were
developed; serum samples containing MUC1 were previously selected by Cancer Associated Serum Antigen (CASA).
Immunoprecipitation (IP) was performed in 9 malignant, benign and normal samples and analyzed by SDS-PAGE and Western
blot. Lewis y and MUC1 expression was studied by immunohistochemistry (IHC). Statistical analysis was performed employing
principal component analysis (PCA), ANOVA, Tukey HSD, Chi square test and classical correlation (p < 0.05).
Results: By ELISA, Lewis y/IgM/CIC levels showed statistically significant differences between breast cancer versus benign and
normal samples; mean ± SD values expressed in OD units were: 0.525 ± 0.304; 0.968 ± 0.482 and 0.928 ± 0.447, for breast
cancer, benign disease and normal samples, respectively, p < 0.05. Lewis y/IgG/CIC did not show any statistically significant
difference. MUC1/IgM/CIC correlated with Lewis y/IgM/CIC. By CASA, 9 samples with MUC1 values above the cut off were
selected and IP was performed, followed by SDS-PAGE and Western blot; bands at 200 kDa were obtained with each MAb in
all the samples. By IHC, with C14 MAb, 47.5%, 31% and 35% of malignant, benign and normal samples, respectively, showed
positive reaction while all the samples were positive with anti-MUC1 MAb; in both cases, with a different pattern of expression
between malignant and non malignant samples.
Conclusion: Our findings support that in breast cancer there was a limited humoral immune response through Lewis y/IgM/
CIC levels detection which correlated with MUC1/IgM/CIC. We also found that Lewis y might be part of circulating MUC1
glycoform structure and also that Lewis y/CIC did not correlate with Lewis y expression.
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Background
Worldwide, breast cancer is the most common cause of
mortality by cancer in female population (GLOBOCAN,
2002, IARC). In order to decrease mortality and to
improve treatment, prevention and early detection
biomarkers are object of study. In this sense, it is very
important to increase knowledge about tumor biology,
which includes studies on risk factors, tumor develop-
ment, dissemination and metastasis.
There is sufficient evidence that blood group related Lewis
antigens are tumor-associated molecules [1]. Changes in
the structure of glycan chains covalently attached to glyc-
oproteins and glycolipids are a common feature of pro-
gression to malignancy [2]. In O-linked glycosylation, the
glycans are added to serine and threonine hydroxyl
groups. Initiation of O-glycosylation in the mammary
gland begins in the Golgi apparatus, is catalysed by a fam-
ily of enzymes which transfer N-acetylgalactosamine (Gal-
NAc) from UDP-GalNAc (UDP-GalNAc polypeptide
glycosyltransferases) to selected serine or threonine resi-
dues in protein chain [3]. After the addition of GalNAc,
various core structures are formed by the addition of dif-
ferent sugars. The terminal epitopes of the O-glycans on
mucins are probably the most important determining
whether the molecule plays a role in cell adhesion phe-
nomena. The epitopes recognized by antibodies related to
the ABO and Lewis blood group antigens are found in this
region. Terminal sugars added in alpha linkage include
sialic acid, fucose, galactose, GalNAc and N-acetylglu-
cosamine (GlcNAc). Some sulphation of sugars in termi-
nal structures may also occur [4].
Lewis y antigen is a difucosylated oligosaccharide with the
chemical structure:
This molecule is expressed predominately during embryo-
genesis while in adults, expression is restricted to granulo-
cytes and epithelial surface [5].
Lewis y and Lewis b antigens are over-expressed by breast,
lung, colon, pancreas, prostate and ovarian cancers, either
at the plasma membrane as a glycolipid or linked to sur-
face receptors such as Erb-B family receptors [1]. Sialyl-
Lewis x and sialyl-Lewis a are complex carbohydrates
which have been also found in breast carcinomas [6].
Breast cancer cell glycans changes are related to glycopro-
tein antigenic differences between carcinoma and normal
mammary gland cells [7]. This phenomenon has been
extensively studied on MUC1 mucin where the aberrant
glycosylation found in tumor cells indicates the appear-
ance of novel glycan epitopes (e.g. STn) as well as the
unmasking of peptide sequences (rev. in [4]). Lewis y oli-
gosaccharides may be part of mucin glycoproteins, which
have characteristic core peptide structures [8]. MUC1,
which is overexpressed in breast cancer, may contain
Lewis y. This mucin has been involved in immune regula-
tion, cell signaling, inhibition of cell-cell and cell-matrix
adhesion [9]. Glycan changes may be important to the
induction of a humoral response [10]. Cell-surface anti-
gens (mainly carbohydrate antigens) have proved to be
unexpectedly potent targets for immune recognition and
attack against human cancers [11].
In a variety of different clinical settings, correlation of
antibodies naturally acquired or vaccine induced with
prognosis improvement is one of the bases for cancer vac-
cines designed primarily for antibody induction [12].
In tumor patients sera, it has been frequently found the
occurrence of variation in circulating immune complexes'
(CIC) levels [13-16]. Although the overall composition of
CIC varies quantitatively even for patients with the same
malignancy, MUC1 has been described as a part of CIC
associated with cancer including breast carcinoma
[13,16,17]. It has been postulated that CIC may play a
protective [15] as well as an impaired [14,18,19] function.
In this sense, the first aim of this research in breast cancer
samples was to evaluate the presence of Lewis y and
MUC1 in circulating immune complexes (Lewis y/CIC
and MUC1/CIC, respectively) and their correlation in
order to investigate their involvement in natural humoral
immune response.
The second aim of this study was to analyze the possible
presence of Lewis y in carbohydrate chains of tumoral
MUC1 glycoprotein isolated from serum.
The third aim was to correlate serum and tissue parame-
ters considered.
Materials and methods
Samples
One hundred and forty six pretreatment serum and tissue
samples proceeding from 76 breast cancer patients, 34
benign breast disease patients and 36 from women with-
out disease were processed. Breast cancer samples were
82% ductal, 13% lobular and 5% mucinous. Disease stag-
ing was: 13% in situ carcinoma, 30% stage I, 34% stage II,
20% stage III and 3% stage IV.
Patients mean age was 55, with a range from 28 to 85
years old.
Breast cancer samples were obtained during tumor resec-
tion surgery and control breast tissue samples from breast
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reduction surgery performed since 2005 to 2007 at differ-
ent hospitals related to the National University of La
Plata, La Plata, Buenos Aires, Argentina. Serum samples
were aliquoted and stored at -70°C until analyzed.
Experiments were done according to the Helsinki Declara-
tion. Informed consent was obtained from all women
included in this study. This research was approved by the
Local Human Investigation Committee, Faculty of Medi-
cal Sciences, National University of La Plata, Argentina.
Monoclonal Antibodies (MAbs)
The following MAbs were assayed: C595, SM3, HMFG1
MAb, directed against different epitopes of a sequence of
20 repeated aminoacids in tandem: variable number of
tandem repeat (VNTR) in the MUC1 protein core [16,20]
and C14 (IgM) MAb, an anti-Lewis y carbohydrate [21].
Methods
ELISA (enzyme linked immunosorbent assay) for the 
detection of circulating immune complexes carrying the 
Lewis y carbohydrate (Lewis y/CIC)
Lewis y/CIC levels were measured by an ELISA method
employing C14 MAb. One hundred μl of 1/100 C14 MAb
diluted in buffer carbonate/bicarbonate pH 9.6 were
adsorbed in each well of 96 wells ELISA microplates (Fal-
con 3912, Microtest III, Becton Dickinson Labware,
Oxnard, USA). After overnight incubation at 4°C, several
washes with sodium phosphate buffer/0.1% Tween 20
(PBST) were done. In each well, 200 μl of blocking buffer
(1%BSA/PBS) were added and plates were incubated at
37°C for 3 h. One hundred μl of 1/20 serum samples
diluted in PBS were applied by triplicate and incubated
overnight at 4°C with the absorbed MAb. Then, plates
were washed with PBST and 1% Triton X-100/PBS; after
that, 1/2000 anti-human IgM or 1/3000 anti-human IgG
horseradish peroxidase conjugates (Dakopatts, Dako Cor-
poration, Copenhagen, Denmark) were added and incu-
bated at 4°C for 2 h. Then, freshly prepared 2,2'-azino-bis
(3-ethylbenzothiazoline)-6-sulphonic acid, (ABTS,
SIGMA, St. Louis, MO, USA) as substrate in sodium citrate
buffer (0.1 M citric acid, 0.2 M PO4HNa2·12H2O), pH 5.0
and 30% H2O2 was added.
Results were expressed as optical density (OD) units at
405 nm. The intra-assay coefficient of variation (CV)
obtained was 3.0% while the inter-assay CV obtained was
10.6%.
ELISA for the detection of MUC1 circulating immune 
complexes (MUC1/CIC)
The technique was developed according to previous
reports [16]. Briefly, MUC1-CIC were measured by an
ELISA test employing a MUC1-specific murine MAb to
capture this glycoprotein: C595 (IgG3, anti-RPAP). The
MAb was adsorbed in Falcon plates (Falcon 3912 Micro-
test III, Becton Dickinson Labware, Oxnard); 100 μl per
well of human serum previously diluted 1:20 in PBS were
applied in duplicate. After incubation and carefully
washed, 100 μl of diluted rabbit anti-human IgM or IgG
immunoglobulins, horseradish peroxidase conjugates
(Dakopatts, Dako Corporation, Copenhagen, Denmark)
were added; afterwards, plates were carefully rinsed and,
100 μl per well of freshly prepared 2,2'-azinobis(3-ethyl-
benzothiazoline)-6-sulphonic acid, ABTS (Sigma Chemi-
cal Co., MO, USA) in sodium citrate buffer (0.1 M citric
acid, 0.2 M PO4HNa2·12H2O), pH 5.0 and 30% H2O2
was added.
For each serum sample, results were expressed as a mean
difference from OD at 405 nm of MAb coated wells; OD
obtained without serum was subtracted from mean OD of
the sample wells.
MUC1 detection by CASA test
MUC1 serum levels were measured by a commercial
CASA test using a dual determinate ELISA (Medical Inno-
vations Limited, Artarmon, Australia). All the steps of the
CASA test were made according to the manufacturers'
instructions. The working range was between 2 and 64
units/ml; samples that exceeded 64 units/ml were diluted
1/5 in negative control and re-assayed. This test utilizes
MAbs BC2 (IgG) and BC3 (IgM), both detecting the pep-
tide epitope APDTR on the VNTR region of the protein
core of the MUC1 mucin; the cut off level was 2 units/ml.
Immunoprecipitation (IP) of MUC1 from serum samples
Five hundred μl of serum were added to 50 μl of protein
A-Sepharose CL-4B (SIGMA, St. Louis, MO, USA); incu-
bated on ice for 30–60 min and spun down at 10000 × g
at 4°C for 10 min. Precleared serum was incubated at 4°C
for 1 h with 10 μl of HMFG1 MAb. Fifty μl protein A-
Sepharose CL-4B was added to immune complexes and
shook on a rotator at 4°C for 1 h. After spinning, the
supernatant was removed and the pellet was washed with
lysis buffer (1% NP40, 1 mM phenyl methyl sulphonyl
fluoride, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0)
(SIGMA, St. Louis, MO, USA). Then, 50 μl of Laemmli
buffer (2% SDS, 5% 2-mercapoethanol, 10% glycerol)
was added and heated to 90–100°C for 10 min. After
spun down, the supernatant was loaded on the gel for
SDS-PAGE analysis.
SDS-PAGE and Western blot (WB) of IP
Supernatants were analyzed under reducing conditions in
SDS-PAGE in a discontinuous buffer system according to
Laemmli [22]. After electrophoresis, gels were either
stained with Coomassie blue (SIGMA, St. Louis, MO,
USA) or they were electrophoretically transferred to nitro-
cellulose membranes [23] which were blocked with PBS/Journal of Experimental & Clinical Cancer Research 2009, 28:121 http://www.jeccr.com/content/28/1/121
Page 4 of 11
(page number not for citation purposes)
5% skimmed milk (blocking buffer). After washing with
PBST, sheets were incubated with either HMFG1 MAb or
C14 MAb diluted in blocking buffer. HMFG1 MAb was
employed undiluted while C14 MAb was diluted 1/100 in
blocking buffer. Sheets were incubated overnight at 4°C
and rinsed with PBST buffer. A final incubation with 1/
400 peroxidase-conjugated anti-human immunoglobu-
lins was performed according to the manufacturer's
instructions (SIGMA, St. Louis, MO, USA). Nitrocellulose
sheets were developed with 3,3'-diaminodiazobenzidine
in PBST containing 30% H2O2.
Immunohistochemistry (IHC)
In all samples, the technique was performed following
standard procedures: paraffin embedded specimens were
treated with 10 mM sodium citrate buffer pH: 6.0 at
100°C for 10 min and incubated overnight at 4°C with
mouse anti-Lewis y and anti-MUC1 MAbs. Negative con-
trols were incubated with PBS instead of MAb. A final
incubation with 1/400 peroxidase-conjugated goat anti-
mouse IgM immunoglobulins (SIGMA, St. Louis, MO,
USA) was performed. The chromogen employed was 3,3'-
diaminodiazobenzidine (SIGMA, St. Louis, MO, USA) in
1%BSA/PBS containing 30% H2O2.
Sections were examined by light microscopy and the anti-
body staining patterns were scored in a semiquantitative
manner. Staining intensity was graded as negative (-), low
(+), moderate (++), or strong (+++). The number of opti-
cal fields in a specimen that were positively stained was
expressed as a percentage of the total number of optical
fields containing tissue. The staining of cytoplasm, plasma
membrane and nucleus was evaluated; cells were consid-
ered positive when at least one of these components was
stained. The pattern of reaction was classified as linear
(membrane reaction), cytoplasmic, or mixed (cytoplas-
mic and membrane) and the positive reaction in gland
lumen content was identified as cellular debris or secre-
tion. Apical and non-apical reactions were also considered
[24].
Statistical analysis
Normality of Lewis y/CIC values and staining intensity
were tested by Shapiro Wilk's and normalized.
In the case of Lewis y/CIC levels, groups were compared
by one way ANOVA followed by Tukey HSD for an une-
qual number of cases post hoc comparisons (p < 0.05).
Statistical differences for immunohistochemical results
were evaluated by the Chi square test. A Principal compo-
nent analysis (PCA) was performed among CIC and clas-
sical correlation among transformed data was performed
(p < 0.05).
Results
Detection of Lewis y/CIC
An ELISA method was developed to detect Lewis y/CIC;
C14 MAb anti-Lewis y was used to capture immune com-
plexes present in serum samples and they were detected
through a peroxidase-conjugated anti-human IgM or IgG.
The reaction was revealed with ABTS as substrate and OD
at 405 nm was measured. Lewis y/IgM/CIC mean values
obtained were the following: 0.525 ± 0.304 (mean ± SD)
OD units for breast cancer samples; 0.968 ± 0.482 for
benign disease and 0.928 ± 0.447 for normal samples. By
ANOVA, standardized Lewis y/IgM/CIC levels from cancer
serum samples were significantly lower than normal and
benign levels (p < 0.05), which did not differ between
them (Fig. 1A).
Lewis y/IgG/CIC OD mean values were: 0.418 ± 0.318;
0.461 ± 0.321 and 0.485 ± 0.267 for breast cancer, benign
and normal samples, respectively. No differences were
found among groups (Fig. 1B). There was no difference in
Lewis y/CIC values among breast cancer types.
Differences among breast cancer stages were studied by
ANOVA on standardized data and any difference was
found neither for Lewis y/IgM/CIC nor for Lewis y/IgG/
CIC levels (Fig. 1C and 1D, respectively).
Detection of MUC1/CIC
MUC1/IgM/CIC mean values obtained were the follow-
ing: 0.320 ± 0.253 (mean ± SD) OD units for breast cancer
samples; 0.453 ± 0.473 for benign disease and 0.406 ±
0.302 for normal samples.
MUC1/IgG/CIC OD mean values were 0.763 ± 0.276;
0.758 ± 0.251 and 0.831 ± 0.359 for breast cancer, benign
and normal samples, respectively. No differences were
found among groups. By ANOVA, standardized MUC1/
CIC levels did not differ among groups.
Immunoprecipitation (IP), SDS-PAGE and WB
MUC1 IP was performed in nine serum samples from
patients with malignant and benign breast diseases as well
as normal females with CASA values above the cut-off
level (2 Units/ml).
In order to isolate MUC1 from sera, pellets obtained by IP
using HMFG1 MAb were treated with lysis and Laemmli's
buffer. All samples and supernatants obtained were ana-
lyzed by SDS-PAGE and WB. Blotting sheets were incu-
bated with C14 MAb and HMFG1 MAb; the latter was
employed to validate IP results. With each MAb, bands at
200 kDa were identified in all selected samples indicating
that MUC1 should contain Lewis y carbohydrate in its
structure. Fig. 2A and 2B show the band obtained from a
normal, a benign and a breast cancer sample when theJournal of Experimental & Clinical Cancer Research 2009, 28:121 http://www.jeccr.com/content/28/1/121
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membranes were incubated with HMFG1 and C14,
respectively. In Fig. 2A it was included a standard of 32
Units/ml of MUC1 provided by CASA test in order to ver-
ify that MUC1 was well obtained after IP.
Lewis y expression by IHC
All samples were analyzed (n = 146); percentages of posi-
tive reaction with C14 MAb in relation to total were as fol-
lows: 47.5% of tumor samples, 31% of benign samples
and 35% of normal samples. Frequency analysis was per-
formed; groups were compared by the Chi square test and
non significant difference was found (p > 0.05).
According to tumor stages the percentages of positivity
(positive samples/total samples of each stage) analyzed
were: 20% of in situ, 36% of stage I; 32% of stage II and
47% of stage III; 33% of stage IV and non significant dif-
ferences were found (p > 0.05).
Although there was any statistical difference, the pattern
of expression differed between malignant and non malig-
nant samples. In cancer specimens, a mixed pattern (cyto-
plasmic and membrane) with non apical reactivity was
more frequently detected at different stages (Fig. 3A–D)
compared with the apical membrane pattern found in
A-D Box-plots represent median values and interquartile ranges of Ley/IgM/CIC (A, C) and Ley/IgG/CIC (B, D) measured by  ELISA in normal, benign and malignant breast samples (A, B), and in different stages (C, D) of breast cancer Figure 1
A-D Box-plots represent median values and interquartile ranges of Ley/IgM/CIC (A, C) and Ley/IgG/CIC (B, D) 
measured by ELISA in normal, benign and malignant breast samples (A, B), and in different stages (C, D) of 
breast cancer. Results are expressed as OD units (405 nm).Journal of Experimental & Clinical Cancer Research 2009, 28:121 http://www.jeccr.com/content/28/1/121
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benign (Fig. 3E) as well as in normal samples (Fig. 3F). In
malignant specimens, variation of Lewis y expression was
a common feature. In several tumors, diffuse and moder-
ate or intense staining was mainly restricted to non apical
cytoplasm; some samples showed a cytoplasmic reaction
with a strong intensity and a granular pattern. Other spec-
imens had a strong reaction limited to the apical part of
the cells (cytoplasm and membrane) in lining glands and
also in lumen content. In some tumor sections, an intense
staining at the apical blebs was found. No nuclear staining
was observed. Fig. 3G shows a normal sample which did
not react with C14 MAb.
MUC1 expression by IHC
All samples were analyzed (n = 146); most malignant,
benign and normal breast samples expressed MUC1;
despite the stage of the disease, malignant tumors showed
reactivity mainly at the cytoplasm with a non-apical pat-
tern although frequently plasmatic membranes also
showed staining (mixed pattern) (Fig. 4A–D). The inten-
sity of the reaction varied from moderate to strong. As it
was expected, benign and normal samples mainly showed
an apical and linear pattern. In Fig. 4E a positive reaction
of a benign breast disease sample is also shown.
Analysis of correlations
In cancer and benign samples, considering intensity of the
IHC reaction versus Lewis y/CIC levels, no significant cor-
relation was found. Lewis y/IgM/CIC and Lewis y/IgG/
CIC values did not correlate as well. In benign samples,
although there was not any statistical significance, Lewis
y/IgG/CIC levels showed a decrease tendency to decrease
while intensity increased (R2 = -0.66).
Normal samples showed a high and significant correla-
tion among staining intensity versus Lewis y/IgM/CIC and
Lewis y/IgG/CIC levels (R2 = 0.885 and 0.967, respec-
tively); in the case of Lewis y/IgM/CIC, a poor but signifi-
cant correlation with Lewis y/IgG/CIC was found (R2 =
0.326, p < 0.05).
In order to explore data, PCA was performed employing
Lewis y/IgM/CIC, Lewis y/IgG/CIC, MUC1/IgG/CIC and
MUC1/IgM/CIC. First and second component explained
68% of data variability; normal samples and benign sam-
ples appeared grouped (PC1 (-)) and separated from can-
cer samples which remained spread. All variables weighed
similar in the model, Lewis y/IgM/CIC, MUC1/IgG/CIC
and MUC1/IgM/CIC predominated PC1 (+) while Lewis
y/IgG/CIC was shared between PC1(+) and PC2(+) (Fig.
5).
Classical multiple correlations (p < 0.05) are shown in
Table 1; in consequence, normal samples appeared
grouped.
Lewis y and MUC1 expression as well as CIC levels did not
show any significant difference among tumor stages.
Discussion
It has been proved that MUC1 is extremely useful for gly-
cosylation studies because changes in the expression and
activity of specific glycosyltransferases have been related
to changes in the O-glycan structures expressed by MUC1
[4]. In a previous report we found that Lewis × antigen was
highly expressed by normal epithelial tissues of mammary
gland and digestive tract [24]. In order to continue the
study of blood group related Lewis antigen involvement
in breast cancer, we have focused this research on the difu-
cosylated Lewis y antigen; this carbohydrate specifically
belongs to the ABH Lewis blood group family which is
overexpressed on the majority of carcinomas including
ovary, pancreas, prostate, breast, colon and non small cell
lung cancers [25-27].
We performed immunoprecipitation of MUC1 from
breast cancer, benign and normal serum samples with
HMFG1 MAb, directed against MUC1 peptide core (DTR)
and isolated the glycoprotein. SDS-PAGE and Western
blot assays were performed with the samples obtained by
IP; nitrocellulose membrane incubation with C14 MAb
showed the same MW band as incubation with HMFG1
MAb in breast cancer, benign and normal samples. These
results indicate that Lewis y could be involved in MUC1
structure. Sikut et al. found that sialyl Lewis a and sialyl
Lewis × epitopes were attached to MUC1 in breast cancer
patients serum samples [28].
A & B: (A) Immunoblotting (IB) of samples obtained by  immunoprecipitation (IP) with HMFG1 MAb from sera and  incubated with HMFG1; 1: MW Standard, 2: normal sample,  3: benign disease sample; 4: breast cancer sample; 5: Standard  of MUC1 (32 U/ml) Figure 2
A & B: (A) Immunoblotting (IB) of samples obtained 
by immunoprecipitation (IP) with HMFG1 MAb from 
sera and incubated with HMFG1; 1: MW Standard, 2: 
normal sample, 3: benign disease sample; 4: breast 
cancer sample; 5: Standard of MUC1 (32 U/ml). (B) IB 
of samples obtained by IP with HMFG1 MAb from sera and 
incubated with C14; 1: normal sample, 2: benign disease sam-
ple; 3: breast cancer sample. Bands at 200 kDa are shown 
with each MAb. The arrows indicate the start of the resolv-
ing gel.Journal of Experimental & Clinical Cancer Research 2009, 28:121 http://www.jeccr.com/content/28/1/121
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During many years, the functions of Lewis y were mostly
unknown although it was described as a differentiation
and onco-developmental antigen [8]. Basu et al. found
that in colon and vulval carcinoma cell lines, sialylated
Lewis a and Lewis y were present in the EGF receptor glyc-
oprotein [29].
In the last decades, further information was achieved; in
breast cancer cell lines, Hellström et al. probed that MAbs
reactive against Lewis y could be internalized and medi-
ated tumor cell killing by antibody-dependent cellular
cytotoxicity (ADCC) and complement dependent cytotox-
icity (CDC) [30]. Furthermore, sialylated Lewis a and
Lewis y were related with apoptosis; in this sense, Rap-
oport and Le Pendu found in colon carcinoma cell lines
such as HT29 in which apoptosis was induced by UV irra-
diation, TNFα and anti-Fas, a major decrease of this anti-
gen as well as Lewis x [31]. On the other hand, in Jurkat
human T cell line, the expression of Lewis x and Lewis y
was enhanced in the cell surface during apoptosis induced
by different agents including anti-Fas antibody [32].
Lewis y is attached to components of the CD66 cluster
which is a member of the carcinoembryonic antigen
(CEA) family and of the immunoglobulin superfamily.
The activation-increase in Lewis y attached to CD66 adhe-
sion molecules implicates a role of the Lewis y determi-
nant in cytoadhesive properties of granulocytes on
trafficking and inflammatory responses [5,33].
In cancer cells, Miyake et al have observed that MAbs
which bind to Lewis y antigen, although cross-reacted
with H and Lewis b, inhibited cell motility and tumor cell
metastasis [34].
Microphotographs of IHC are shown (×400) Figure 3
Microphotographs of IHC are shown (×400). Ductal 
breast carcinoma sections at stages (A) I, (B) II, (C) III and 
(D) IV incubated with C14 anti-Lewis y MAb. A mainly non-
apical cytoplasmic positive reaction is shown in all samples. 
(E) A benign and (F) a normal breast samples with an apical 
and linear pattern are shown. (G) A normal sample which did 
not react with C14 is depicted.
Microphotographs of IHC of ductal breast carcinoma sam- ples at different stages are shown (×400) Figure 4
Microphotographs of IHC of ductal breast carcinoma 
samples at different stages are shown (×400). (A) Stage 
I, (B) II, (C) III and (D) IV sections incubated with anti-MUC1 
MAbs reacted with a non-apical mainly mixed pattern; in (E) a 
benign sample shows an apical linear positive reaction; con-
tent of a ductal lumen is also stained.Journal of Experimental & Clinical Cancer Research 2009, 28:121 http://www.jeccr.com/content/28/1/121
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We employed C14 MAb which recognizes circulating anti-
gen in serum and tumor sections of patients bearing a
variety of malignancies [35]. In this study by IHC, with
this MAb, we found a positive reaction in 47.5% of breast
tumor samples, showing a different pattern of expression
among malignant, benign and normal samples; neverthe-
less; no statistically significant difference in percentage of
expression was found. In cancer samples, we did not find
any significant difference among different stages. Our
results are in agreement with Madjd et al since they found
that Ley/b is expressed in 44% of breast cancer samples,
employing SC101 MAb although this MAb reacts with
both Lewis y and Lewis b [1].
On the other hand, as it was not surprising, MUC1 was
detected in all samples employing many anti-MUC1 anti-
bodies (16); in consequence, correlation analysis was not
necessary.
Principal Component Analysis (PCA) was performed employing Lewis y/IgM/CIC, Lewis y/IgG/CIC, MUC1/IgG/CIC and  MUC1/IgM/CIC Figure 5
Principal Component Analysis (PCA) was performed employing Lewis y/IgM/CIC, Lewis y/IgG/CIC, MUC1/
IgG/CIC and MUC1/IgM/CIC. First and second component explained 68% of data variability; normal samples and benign 
samples appeared grouped (PC1 (-)) and separated from cancer samples which remained spread. All variables weighed similar 
in the model, Lewis y/IgM/CIC, MUC1/IgG/CIC and MUC1/IgM/CIC predominated PC1 (+) while Lewis y/IgG/CIC was shared 
between PC1(+) and PC2(+). Rays and circles represent CIC analyzed and cases, respectively. C: cancer, B: benign, N: normal.
Table 1: Spearman correlation coefficients among CIC levels
Le y/IgM/CIC Le y/IgG/CIC MUC1/IgM/CIC MUC1/IgG/CIC
Le y/IgM/CIC 1 0.2147 0.4038 0.2847
Le y/IgG/CIC 0.2147 1 0.0739 0.3362
MUC1/IgM/CIC 0.4038 0.0739 10 . 5 1 1 8
MUC1/IgG/CIC 0.2847 0.3362 0.5118 1
Bold letters indicate significant correlations.Journal of Experimental & Clinical Cancer Research 2009, 28:121 http://www.jeccr.com/content/28/1/121
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Klinger et al confirmed that the majority of cancer cells
derived from epithelial tissue express Lewis y type difuco-
sylated oligosaccharides on their plasma membranes;
they have also found that ABL 364 MAb against this car-
bohydrate which is present in erbB receptor side chains
are capable of inhibiting erbB receptor mediated signaling
[36]. Other authors found a novel function for soluble
Ley/H as an endothelial-selective and cytokine inducible
as well as a potent angiogenic mediator in both in vitro
and in vivo bioassays [37].
Cancer antigens expressed at the cell surface are generally
glycolipids or glycoproteins [12,38] which may express in
their molecules blood group related Lewis antigens [2].
The non appropriate biosynthesis or processing of carbo-
hydrate structures may contribute to the disordered
behaviour of tumor cells [39]. Lewis y carbohydrate may
participate in natural humoral immune response; anti-
bodies are ideally suited for eradicating pathogens from
bloodstream and early tissue invasion. With regard to can-
cer cells, passively administered and vaccine induced anti-
bodies have accomplished this concept, limiting tumor
cells and systemic or intraperitoneal micrometastases in a
variety of preclinical models [12]. Many protocols devel-
oping anti-Lewis y vaccines have been performed
[12,40,41].
In this report, we found that Lewis y/IgM/CIC levels cor-
related with Lewis y/IgG/CIC levels and MUC1/CIC (IgG
and IgM) levels and also that Lewis y/IgG/CIC levels cor-
related with MUC1/IgG/CIC levels. These correlations
may be related with the fact that MUC1 may be a carrier
of Lewis y epitope. Von Mensdörff-Pouilly et al [42] found
that naturally occurring MUC1 antibodies seem to check
disease spread in breast cancer patients, possibly by
destroying blood-borne isolated disseminated tumor cells
(micrometastases) which eventually could lead to meta-
static disease and death. Silk et al found significantly
higher anti-MUC1 IgG levels in abnormal versus normal
colorectal location [43].
Correlation of antibodies, naturally acquired or vaccine-
induced, with improved prognosis in a variety of different
clinical settings is one of the bases for cancer vaccines
designed for antibody induction. It is essential to ensure
that immune responses against tumor antigens can
destroy tumor cells but not normal ones. An important
immune response against a tumor specific antigen would
be irrelevant if a tumor cell mutates in such a way that it
no longer expressed its specific antigen avoiding cells
destruction by the immune system [44]. Therefore, it is
remarkably outstanding to study the natural humoral
immune response through immune complexes detection.
With the aim of enhancing immune response in breast
cancer patients, vaccines constructed with glycolipids or
glycoproteins derivatives as immunogens are being devel-
oped.
Conclusion
By IHC, tumor and tissue Lewis y and MUC1 expression
was evaluated; although we did not find any statistically
significant difference among malignant, benign and nor-
mal samples, the pattern of expression differed. Besides,
no correlation between clinical pathological parameters
(age, type, stage or grade) and IHC expression was found.
On the other hand, humoral immune response was stud-
ied measuring Lewis y/IgM/CIC levels and a statistically
significant difference among breast cancer serum samples
versus normal and benign specimens was found, being
lower in cancer samples.
Our findings also support that, in breast cancer, Lewis y
may be part of circulating MUC1 glycoform structure and
that Lewis y/CIC do not correlate with Lewis y expression.
This lack of correlation may be related to a limited
humoral immune response against these molecules in
cancer patients which could be due to the escape from the
immunosurveillance of the host.
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